Fort Towson

• What I think should be changed (include citations):

First of all, I would like to make transparent that I'm working in QIAGEN's public relations department. As this implies a COI for this article, I suggest the changes I would like to make here instead of implementing them directly.

I would like to restore the "Acquisitions" section of QIAGEN's Wikipedia article after it had been deleted due to the lack of reliable sources. I have researched suitable sources that should match the Wikipedia guidelines. Please let me know if sources are not compliant with the guidelines so I can try to find alternatives.

I would like to add the following and have included the sources:

Acquisitions In 2004, QIAGEN acquired key assets of Molecular Staging, Inc.^[1] Two years later, QIAGEN established its Asia regional headquarters in Shanghai. In 2007 sales reached US$649.8 million and the number of employees surpassed 2,600. QIAGEN acquired Digene for US$1.6 billion, furthering QIAGEN in molecular diagnostics by revenue and diagnostics for disease prevention.^[2]

In 2009, QIAGEN began building its Personalized Healthcare business through the acquisition of DxS Ltd, in a deal valued at US$95 million^[3] and it acquired SABiosciences Corp. in a deal valued at US$90 million.^[4] At the end of 2009 QIAGEN surpassed the US$1 billion revenue mark and had over 3,500 employees. QIAGEN became one of the first companies to release a clinically verified diagnostic test for the detection of H1N1, more commonly known as Swine Flu.^[5]

In 2010, QIAGEN acquired ESE GmbH, giving the company access to point of need testing devices for the application of molecular diagnostic tests without laboratory infrastructure.^[6]

In 2011, QIAGEN acquired Ipsogen S.A. for US$101 million, adding to the company's product and IP portfolio in the blood cancer space.^[7] QIAGEN also acquired Cellestis Limited for US$374 million, giving the company access to QuantiFERON technology for disease detection and prevention.^[8] The company added two new offices in the Asia Pacific region in New Delhi, India and Taipei, Taiwan. The company announced a comprehensive restructuring program to focus on high-growth areas such as personalized medicine and business in emerging markets. The program includes workforce reduction and internal restructuring affecting approximately 10% of the company's 3,900 positions.^[9]

In 2013, QIAGEN acquired Ingenuity Systems.^[10] QIAGEN also acquired CLC bio, which offers bioinformatics analysis software.^[11] In 2015, QIAGEN acquired AdnaGen's circulating tumor cell enrichment technology.^[12] QIAGEN also acquired Enzymatic enzyme solutions.^[13]

In March 2015, a management buyout of QIAGEN Marseille led to the creation of HalioDx.^[14] In late 2015 the GeneReader NGS System was launched,^[15] and the acquisition of Mo Bio Laboratories was completed.^[16]

In 2016, QIAGEN acquired the Danish molecular diagnostics company Exiqon.^[17]

In 2017, QIAGEN acquired OmicSoft Corporation, a leading provider of highly curated public datasets.^[18]

In 2018, QIAGEN transferred its listing to New York Stock Exchange.^[19] In April 2018, QIAGEN acquired the Spanish firm STAT-Dx and launched the QIAstat-Dx molecular diagnostics platform.^[20]

In 2019, QIAGEN announced the acquisition of Formulatrix assets to develop a digital PCR platform.^[21] An additional acquisition of N-of-One, a privately held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data, to expand its QCI bioinformatics offerings.^[22] In October 2019 QIAGEN entered into an agreement with Illumina granting QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina's diagnostic instruments.^[23]

In September 2020 QIAGEN announced the acquisition of Michigan-based NeuMoDx Inc. to market two fully integrated systems for automated PCR.^[24]

In May 2022, QIAGEN acquired the majority stake in BLIRT S.A., adding new R&D and manufacturing capabilities for customized and standardized recombinant enzymes, as well as molecular biology reagents.^[25]

In January 2023, the business announced its intention to acquire Verogen for $150 million. This deal included acquiring GEDmatch.^[26]

• Why it should be changed:

The acquisitions are an important part of QIAGEN's history and development and should therefore be part of the article.

Editorqiagen (talk) 11:42, 1 March 2024 (UTC)[reply]